| Item No | Description |
|---|---|
| 61523 | Lung – Solitary Pulmonary Nodule Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed. |
| 61524 | Breast Cancer - Staging of locally advanced (Stage III) disease Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy |
| 61525 | Breast Cancer - Suspected metastasis or local/regional recurrence Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy |
| 61529 | Non Small Cell Lung Carcinoma Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned. |
| 61538 | Malignant Brain Tumour FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. |
| 61541 | Colorectal Carcinoma – Restaging Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy. |
| 61553 | Melanoma Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy. |
| 61559 | Epilepsy FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery. |
| 61560 | Alzheimer’s disease FDG PET study of the brain, performed for the diagnosis of Alzheimer’s disease, if clinical evaluation is equivocal. No Brain SPECT study in the previous 12 months. |
| 61565 | Ovarian Carcinoma – Restaging Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy. |
| 61571 | Carcinoma Uterine Cervix – Staging Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent. |
| 61575 | Carcinoma Uterine Cervix – Restaging Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent. |
| 61577 | Oesophageal or GEJ Carcinoma Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy. |
| 61598 | Head and Neck Cancer – Staging Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer. |
| 61604 | Head and Neck Cancer (Residual) – Restaging Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy. |
| 61610 | Metastatic SCC Cervical Lymph Nodes – Unknown Primary Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes. |
| 61620 | Lymphoma – Initial Staging Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin’s or non-Hodgkin’s lymphoma. |
| 61622 | Lymphoma – Therapy Response Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin’s or non-Hodgkin’s lymphoma. |
| 61628 | Lymphoma – Restaging Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin’s or non-Hodgkin’s lymphoma. |
| 61632 | Lymphoma – Post Second Line Chemotherapy Whole body FDG PET study to assess response to second-line chemotherapy when stem cell transplantation is being considered for Hodgkin’s or non-Hodgkin’s lymphoma. |
| 61640 | Bone or Soft Tissue Sarcoma – Staging Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable. |
| 61646 | Residual or Recurrent Sarcoma – Restaging Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent. |
| 61612 | Rare or Uncommon Cancer - Initial Staging Whole body FDG PET study for the initial staging of a rare or uncommon cancer (less than 12 cases per 100,000 persons per year) that is a typically FDG avid cancer, and there is at least a 10% likelihood that the PET study result will inform a significant change in management for the patient. |
